ABOUT US
Company
Leadership
Board
Advisors
History
Investors
Join us
SCIENCE
LDHA
PIPELINE
NEWS
CONTACT US
中文

NEWS

META Nominates MP-5342 as First Pre-clinical Candidate for Inflammatory Bowel Disease 2025/10/15

META Nominates MP-5342 as First Pre-clinical Candidate for Inflammatory Bowel Disease 2025/10/15

The first candidate molecule derived from the innovative immunometabolism platform has completed preclinical development and is approaching the IND-enabling study stage.
Showcase 2025.10.15
All Progress Spotlight Honor Showcase Care
META to Present at the 44th Annual J.P. Morgan Healthcare Conference

META to Present at the 44th Annual J.P. Morgan Healthcare Conference

The 44th Annual J.P. Morgan Healthcare Conference will take place January 12–15 in San Francisco, USA.
Showcase
2026.01.10
META Named to 2025 Deloitte China Seed Award for Pharmaceutical & Health List

META Named to 2025 Deloitte China Seed Award for Pharmaceutical & Health List

Deloitte China has recently announced its 2025 Technology Fast Program lists. META stood out among numerous outstanding applicants, earning a place on the **2025 Deloitte China Seed Award for Pharmaceutical & Health** list, recognized for its pioneering innovation in immunometabolism, substantial R&D translational capabilities, and significant technological potential.
Showcase
2025.12.19
META Officially Joins Johnson & Johnson Innovation – JLABS

META Officially Joins Johnson & Johnson Innovation – JLABS

META has officially been welcomed into Johnson & Johnson Innovation – JLABS, the global healthcare giant’s premier life science incubator, becoming one of its resident companies. This marks a significant milestone in META’s corporate history.
Showcase
2025.05.26
META Pharmaceuticals, a pioneer biotech in immune-metabolism, raised 15M USD to accelerate its pipeline development

META Pharmaceuticals, a pioneer biotech in immune-metabolism, raised 15M USD to accelerate its pipeline development

As a pioneer in the field of immuno-metabolism, META Pharmaceuticals Inc. (META Pharmaceuticals) has completed a 15M USD seed and Pre-A funding round. The name META derives from the word metabolism that symbolizes the company’s focus on the cross-regulation between metabolism and immunity.  
Showcase
2022.06.13

Discovery Begins Asking How Life Works

Copyright © 2026 Meta Pharmaceuticals Inc.
粤ICP备2026058060号